Literature DB >> 34198652

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Chia-Jung Li1,2, Yen-Dun Tony Tzeng3,4, Yi-Han Chiu5, Hung-Yu Lin6, Ming-Feng Hou7, Pei-Yi Chu8,9,10,11.   

Abstract

Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies.

Entities:  

Keywords:  biomarkers; breast cancer; pathogenesis; target therapy

Year:  2021        PMID: 34198652     DOI: 10.3390/cancers13122978

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  Integrated analysis of pivotal biomarker of LSM1, immune cell infiltration and therapeutic drugs in breast cancer.

Authors:  Yen-Dun Tony Tzeng; Kuan-Hao Tsui; Ling-Ming Tseng; Ming-Feng Hou; Pei-Yi Chu; Jim Jinn-Chyuan Sheu; Chia-Jung Li
Journal:  J Cell Mol Med       Date:  2022-06-12       Impact factor: 5.295

2.  Downregulation of ATP binding cassette subfamily a member 10 acts as a prognostic factor associated with immune infiltration in breast cancer.

Authors:  Pei-Yi Chu; Yen-Dun Tony Tzeng; Kuan-Hao Tsui; Ching-Yu Chu; Chia-Jung Li
Journal:  Aging (Albany NY)       Date:  2022-03-05       Impact factor: 5.682

Review 3.  Current landscape of personalized clinical treatments for triple-negative breast cancer.

Authors:  Jun Zhang; Yu Xia; Xiaomei Zhou; Honghao Yu; Yufang Tan; Yaying Du; Qi Zhang; Yiping Wu
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.